Research Topics
| Markus BickelSummaryAffiliation: Zentrum der Inneren Medizin Country: Germany Publications
| Collaborators
|
Detail Information
Publications
End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 yearsM Bickel
Department of Infectious Disease, Goethe University, Frankfurt Main, Germany
HIV Med 14:127-35. 2013..Renal disease is a common and serious complication in HIV-infected patients...- Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patientsMarkus Bickel
HIVCENTER, Clinic of the Goethe University, Frankfurt, Germany
Clin Infect Dis 52:122-7. 2011..gov NCT01017172)... - Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patientsMarkus Bickel
HIVCENTER, Frankfurt, Germany
AIDS 24:F31-5. 2010..To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172)... - Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapyChristoph Stephan
Infectious Diseases Unit at Medical Department No 2, Hospital of the Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt, Germany
Med Microbiol Immunol 202:117-24. 2013..Viral detection >200 copies/ml was associated with decreasing CD4-cell slopes and emergence of major mutations, supporting this as benchmark for virological failure definition on PI therapy... 
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirMarkus Bickel
HIVCENTER, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
J Antimicrob Chemother 65:999-1004. 2010..The introduction of raltegravir, which is not metabolized by the cytochrome system, may allow concomitant treatment without dose adaptation...- Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy settingAnnette Haberl
HIVCENTER, Medical Clinics II, J W Goethe University Hospital, Frankfurt am Main, Germany
Eur J Clin Pharmacol 66:375-81. 2010..We performed a matched-pairs analysis on 24 patients (12 men/women) taking atazanavir/ritonavir 300/100 mg daily plus reverse transcriptase inhibitors, with (n = 12) or without (n = 12) methadone co-administration... - Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypesMartin Stürmer
Johann Wolfgang Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
Antimicrob Agents Chemother 55:5362-6. 2011..Current algorithms appear suboptimal for interpretation of resistance to tipranavir in non-B subtypes; increased scores might reflect algorithm bias rather than "natural resistance.".. 
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyMarkus Bickel
HIV Medical Treatment and Research Unit, Frankfurt, Germany
Scand J Infect Dis 40:36-9. 2008..006). These results suggest that the achieved reduction of VAT using r-hGH in lipodystrophic HIV+ patients is in part maintained after a median follow-up of 9 months...- Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosisMarkus Bickel
HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
Scand J Infect Dis 37:520-2. 2005..Plasma levels of efavirenz were 10 times the upper limit and remained elevated (at twice the upper limit) 4 weeks after cessation of therapy. Efavirenz resistance (K103N) developed and was probably due to 'functional' monotherapy... - Renal AA-amyloidosis in intravenous drug users--a role for HIV-infection?Oliver Jung
Department of Infectious Disease, Goethe University, Frankfurt Main, Germany
BMC Nephrol 13:151. 2012..Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades... - Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display libraryMingkui Zhou
Georg Speyer Haus, Institute for Biomedical Research, Frankfurt, Germany
Eur J Immunol 43:499-509. 2013..Thus, this new epitope represents a promising candidate for further analysis in view of HIV vaccine development... - Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuseMarkus Bickel
Department of Internal Medicine ICU, J W Goethe University, Frankfurt, Germany
Eur J Emerg Med 12:306-8. 2005..Magic mushrooms are becoming increasingly fashionable among drug users, as they are believed to be more harmless than other hallucinogenic designer drugs. So far, little is known about their possible severe side effects...